Bristol Myers Squibb (CELG-RI) Total Current Liabilities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Total Current Liabilities for 18 consecutive years, with $18.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 32.22% year-over-year to $18.7 billion in Q2 2026; TTM through Jun 2026 was $18.7 billion, a 32.22% decrease from a year earlier, with the FY2025 full-year figure at $23.4 billion, down 1.5% from the prior year.
• Total Current Liabilities was $18.7 billion for Q2 2026 at Bristol Myers Squibb, down from $19.2 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $28.1 billion in Q3 2025 and troughed at $18.7 billion in Q2 2026.
• A 5-year average of $22.6 billion and a median of $22.7 billion in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 35.3% in 2024 and plunged 32.22% in 2026, its largest moves.
• Over 5 years, Total Current Liabilities stood at $21.9 billion in 2022, then advanced by 1.7% to $22.3 billion in 2023, then rose by 6.79% to $23.8 billion in 2024, then fell by 1.5% to $23.4 billion in 2025, then dropped by 20.32% to $18.7 billion in 2026.
• The last three Total Current Liabilities figures came in at $18.7 billion (Q2 2026), $19.2 billion (Q1 2026), and $23.4 billion (Q4 2025), per Business Quant data.